Articles by Philip Chong
You've Received A Force Majeure Notice. What Now? - A Practical Guide For Businesses On The Receiving End Of Force Majeure Claims
[co-author: Alex Hiendl] Global disruption seems to be the new normal state of the world. Even regional events can trigger cascading effects across interconnected economies. From the Covid-19 pandemic to the Russia-Ukraine conflict and the Middle East crisis, businesses face rolling shocks that ripple across borders and supply chains. The consequences cut across industries: volatile energy prices, supply-chain breakdowns, project delays, and margin-squeezing cost escalation.
Like the rest of biopharma investors, corporate VCs love oncology
As oncology rounds backed by big pharma VCs have receded, CNS rounds have increased steadily, from six in 2015 to 14 in 2018.
Are the big corporate venture arms retreating?
The chart above shows cumulative investments over the past decade, and a flattening of the curves can be seen with several names. This could simply be a blip, of course, although the venture team at SR One was recently reported to be exploring a separation from its parent company Glaxo, which makes the declining numbers at that firm more notable.
The sellside’s mid-term forecast: sunny with few hints of rain
This analysis was conducted by comparing EvaluatePharma’s current consensus forecasts for 2022 with the archived consensus that was compiled at the end of 2017. Not all products attract sales forecasts from sellside analysts, so this is an underestimate of the total drugs market; the analysis also excludes generics. However, it does provide a snapshot of the most important products for manufacturers of novel medicines, the fortunes of which are closely scrutinised by investors.
Topping 2018 drug approvals will be a tall order
Remember the number 62. That is the new benchmark for US drug approvals set in 2018 by a biopharma sector propelled by billions of dollars in investment and a regulatory agency in overdrive. The US government’s shutdown must cast some doubt over whether such a feat can be repeated in 2019. While user fee-supported drug reviews are so far continuing, the FDA is running out of that revenue stream, and no new applications can be received.
Japanese biopharma rules mid-cap returns
The year-end wild ride on the stock exchanges led to some unexpected companies topping the table when it came to mid- and small-cap biopharma. So it was that Japanese groups, led by Sumitomo Dainippon Pharma, were the top mid-cap gainers in 2018. The big fallers had the usual troubles of clinical failure or strategic misadventures. Perrigo scored a triple this year with an unexpected management shift, an unpopular business unit spin-off and a surprise year-end tax bill from Irish authorities.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Philip
Contact Philip, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack